AWA
ACAD icon

Arete Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Arete Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,500
Closed -$307K – 322
2025
Q4 		$307K Sell
11,500
-2,125
-16% -$50.8K 0.02% 336
2025
Q3 		$291K Hold
13,625
– – 0.02% 617
2025
Q2 		$294K Hold
13,625
– – 0.02% 566
2025
Q1 		$226K Sell
13,625
-75
-0.5% -$1.36K 0.02% 631
2024
Q4 		$251K Buy
13,700
+1,875
+16% +$30.3K 0.02% 615
2024
Q3 		$182K Sell
11,825
-3,875
-25% -$64.6K 0.02% 661
2024
Q2 		$255K Sell
15,700
-300
-2% -$4.84K 0.02% 573
2024
Q1 		$296K Buy
+16,000
New +$396K 0.03% 346
2023
Q4 		– Sell
-16,600
Closed -$346K – 743
2023
Q3 		$346K Buy
16,600
+3,950
+31% +$107K 0.06% 316
2023
Q2 		$303K Sell
12,650
-4,250
-25% -$94.5K 0.03% 495
2023
Q1 		$318K Sell
16,900
-378
-2% -$7.2K 0.03% 456
2022
Q4 		$275K Buy
+17,278
New +$270K 0.02% 478

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Arete Wealth Advisors's ACAD Position: Q1 2026 in Review

Arete Wealth Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 11,500 shares — an estimated $307K sold.

Arete Wealth Advisors first reported a position in ACAD in Q4 2022 and held it in 12 quarters. The position peaked at $346K in Q3 2023. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Arete Wealth Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arete Wealth Advisors sold 11,500 Acadia Pharmaceuticals shares in Q1 2026, an estimated $307K.
  • Arete Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Arete Wealth Advisors's Acadia Pharmaceuticals position peaked at $346K in Q3 2023.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Arete Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.